CAR-T Cell Therapy Market is expected to hit US$ 20.4 billion by 2033 | Major Companies - Novartis AG, Gilead Sciences, Inc., Bristol Myers Squibb company, Johnson & Johnson, Pfizer Inc.

Market Size and Growth:

The Global CAR-T Cell Therapy Market size reached US$ 4.8 billion in 2024 and is expected to reach US$ 20.4 billion by 2033, growing at a CAGR of 16.3% during the forecast period 2025-2033.

DataM Intelligence has published a new research report on "CAR-T Cell Therapy Market Size 2026". The report explores comprehensive and insightful Information about various key factors like Regional Growth, Segmentation, CAGR, Business Revenue Status of Top Key Players and Drivers. The purpose of this report is to provide a telescopic view of the current market size by value and volume, opportunities, and development status.

Get a Free Sample PDF Of This Report (Get Higher Priority for Corporate Email ID): https://datamintelligence.com/download-sample/car-t-cell-therapy-market?sz

Chimeric Antigen Receptor T-cell (CAR-T) cell therapy is an advanced immunotherapy that involves genetically modifying a patient's T cells to recognize and destroy cancer cells. The CAR-T Cell Therapy Market encompasses the research, development, manufacturing, and commercialization of personalized treatments targeting hematologic malignancies and emerging solid tumors. It includes approved products, clinical-stage pipelines, supporting technologies, and healthcare services. Market growth is driven by rising cancer prevalence, regulatory approvals, expanding indications, and innovations in gene editing and cell processing platforms.

Recent Key Developments of United States:

✅ December 2025: FDA approves lisocabtagene maraleucel for marginal zone lymphoma.
The U.S. FDA approved Bristol Myers Squibb's Breyanzi (lisocabtagene maraleucel), a CD19-directed CAR-T therapy, for adults with relapsed/refractory marginal zone lymphoma after at least two prior therapies. This marks the first CAR-T approval for this lymphoma subtype, expanding options for hematologic cancers.

✅ December 2025: FasTCAR BCMA x CD19 therapy shows strong results in multiple myeloma.
Preliminary phase 1b/2 data from the DURGA-1 study presented at the 2025 ASH meeting demonstrated nearly universal objective responses with AZD0120, a rapid-manufactured dual-targeted CAR-T for relapsed/refractory multiple myeloma. This advances next-generation manufacturing to improve accessibility.​

✅ December 2025: FDA outlines RCT preference for new oncology CAR-T approvals.
FDA leaders published guidance favoring randomized clinical trials with survival endpoints for initial CAR-T approvals in oncology, aiming to strengthen evidence over single-arm studies. This shift targets ethical comparisons against standard and prior CAR-T therapies.

✅ December 2025: First patient dosed in Imviva's TENACITY-01 CAR-T trial.
Imviva Biotech dosed the initial U.S. patient in the phase 1 TENACITY-01 trial for CTD402, a CAR-T candidate, with interim data anticipated soon after. This highlights ongoing pipeline momentum in novel CAR-T constructs.​

Recent Key Developments of Japan:

✅ January 2026: Regulatory acceleration for CAR-T approvals and reimbursements.
Japanese authorities fast-tracked approvals and insurance reimbursements for imported and domestic CD19-targeted CAR-T therapies targeting lymphoma and leukemia. This supports broader access amid rising hematologic cancer cases.​

✅ January 2026: Clinical data updates at Tokyo oncology congresses.
Local and global firms shared enhanced safety and efficacy data for CAR-T in multiple myeloma and ALL from Asian cohorts at major Tokyo events. These presentations underscore adaptation for Japanese patient populations.​

✅ December 2025: CAR-T integration expands in specialized cancer centers.
Adoption grew in Japan's university hospitals and cancer centers due to higher diagnosis rates and infrastructure for advanced hematologic treatments. Government biotech investments further propelled R&D and commercialization.

✅ November 2025: A-SEEDS partners for novel CAR-T trial manufacturing.
A-SEEDS (Japan) announced a manufacturing collaboration with Cell Therapies (Australia) to support clinical trials of an innovative CAR-T therapy. This partnership accelerates Japan's novel CAR-T development for global trials.​

List of the Key Players in the CAR-T Cell Therapy Market:

Novartis AG
Gilead Sciences, Inc.
Bristol Myers Squibb company
Johnson & Johnson
Autolus Therapeutics
Pfizer Inc.
BioNTech SE.
Merck KGaA
Allogene Therapeutics
Atara Biotherapeutics, Inc.

Speak to Our Analyst and Get Customization in the report as per your requirements: https://datamintelligence.com/customize/car-t-cell-therapy-market?sz

This Report Covers:

✔ Go-to-market Strategy.

✔ Neutral perspective on the market performance.

✔Development trends, competitive landscape analysis, supply side analysis, demand side analysis, year-on-year growth, competitive benchmarking, vendor identification, and other significant analysis, as well as development status.

✔Customized regional/country reports as per request and country level analysis.

✔ Potential & niche segments and regions exhibiting promising growth covered.

✔ Analysis of Market Size (historical and forecast), Total Addressable Market (TAM), Serviceable Available Market (SAM), Serviceable Obtainable Market (SOM), Market Growth, Technological Trends, Market Share, Market Dynamics, Competitive Landscape and Major Players (Innovators, Start-ups, Laggard, and Pioneer).

Segments Covered in the CAR-T Cell Therapy Market:

By Therapy Type: Autologous CAR-T Cell Therapy, Allogeneic CAR-T Cell Therapy.

By Drug Type: Abecma, Breyanzi, Carvykti, Tecartus, Kymriah, Yescarta.

By Target Antigen: CD19, BCMA (B-cell maturation antigen), CD20, CD22, CD30, CD33, GD2, HER2, Others.

By Application: Acute Lymphoblastic Leukemia (ALL), Non-Hodgkin Lymphoma, Chronic Lymphocytic Leukemia (CLL), Multiple Myeloma (MM), Follicular Lymphoma, Others.

Regional Analysis:

⇥ North America (U.S., Canada, Mexico)

⇥ Europe (U.K., Italy, Germany, Russia, France, Spain, The Netherlands and Rest of Europe)

⇥ Asia-Pacific (India, Japan, China, South Korea, Australia, Indonesia Rest of Asia Pacific)

⇥ South America (Colombia, Brazil, Argentina, Rest of South America)

⇥ Middle East & Africa (Saudi Arabia, U.A.E., South Africa, Rest of Middle East & Africa)

Looking For Full Report? Get it Here: https://www.datamintelligence.com/buy-now-page?report=car-t-cell-therapy-market

Chapter Outline:

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 2: key insights, key emerging trends, etc.

Chapter 3: Manufacturers competitive analysis, detailed analysis of CAR-T Cell Therapy manufacturers competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product revenue, gross margin, product introduction, recent development, etc.

Chapter 5 & 6: Revenue of CAR-T Cell Therapy in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.

Chapter 7: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 8: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: The main points and conclusions of the report.

Unlock 360° Market Intelligence with DataM Subscription Services: https://www.datamintelligence.com/reports-subscription

People Also Ask:

◆ How big is the CAR-T Cell Therapy Market in 2026?
◆ What is the projected growth rate of the CAR-T Cell Therapy Market through 2034?
◆ Who are the key players in the CAR-T Cell Therapy Market?
◆ Which region is expected to dominate the industry during the forecast period?

Contact Us -
Company Name: DataM Intelligence
Contact Person: Sai Kiran
Email: Sai.k@datamintelligence.com
Phone: +1 877 441 4866
Website: https://www.datamintelligence.com

About Us -
DataM Intelligence is a Market Research and Consulting firm that provides end-to-end business solutions to organizations from Research to Consulting. We, at DataM Intelligence, leverage our top trademark trends, insights and developments to emancipate swift and astute solutions to clients like you. We encompass a multitude of syndicate reports and customized reports with a robust methodology.
Our research database features countless statistics and in-depth analyses across a wide range of 6300+ reports in 40+ domains creating business solutions for more than 200+ companies across 50+ countries; catering to the key business research needs that influence the growth trajectory of our vast clientele.

This release was published on openPR.